UBS Group’s NRC Health Common Stock NRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $402K | Sell |
23,687
-4,777
| -17% | -$81.2K | ﹤0.01% | 6235 |
|
|
2025
Q4 | $534K | Sell |
28,464
-11,191
| -28% | -$169K | ﹤0.01% | 6040 |
|
|
2025
Q3 | $507K | Buy |
39,655
+19,713
| +99% | +$296K | ﹤0.01% | 6084 |
|
|
2025
Q2 | $335K | Buy |
19,942
+10,783
| +118% | +$146K | ﹤0.01% | 6356 |
|
|
2025
Q1 | $117K | Sell |
9,159
-4,317
| -32% | -$69.3K | ﹤0.01% | 6929 |
|
|
2024
Q4 | $238K | Buy |
13,476
+4,020
| +43% | +$76.2K | ﹤0.01% | 6348 |
|
|
2024
Q3 | $216K | Buy |
9,456
+2,854
| +43% | +$64.5K | ﹤0.01% | 5816 |
|
|
2024
Q2 | $152K | Sell |
6,602
-10,976
| -62% | -$338K | ﹤0.01% | 5860 |
|
|
2024
Q1 | $696K | Sell |
17,578
-183
| -1% | -$7.24K | ﹤0.01% | 4918 |
|
|
2023
Q4 | $703K | Buy |
17,761
+9,577
| +117% | +$401K | ﹤0.01% | 4803 |
|
|
2023
Q3 | $363K | Sell |
8,184
-1,892
| -19% | -$82.6K | ﹤0.01% | 4905 |
|
|
2023
Q2 | $438K | Buy |
10,076
+4,125
| +69% | +$181K | ﹤0.01% | 4933 |
|
|
2023
Q1 | $259K | Buy |
5,951
+1,015
| +21% | +$44.8K | ﹤0.01% | 5195 |
|
|
2022
Q4 | $184K | Buy |
4,936
+4,861
| +6,481% | +$188K | ﹤0.01% | 5529 |
|
|
2022
Q3 | $3K | Sell |
75
-205
| -73% | -$7.59K | ﹤0.01% | 9561 |
|
|
2022
Q2 | $11K | Sell |
280
-1,838
| -87% | -$66.5K | ﹤0.01% | 7827 |
|
|
2022
Q1 | $84K | Sell |
2,118
-2,493
| -54% | -$97.6K | ﹤0.01% | 6046 |
|
|
2021
Q4 | $192K | Buy |
4,611
+4,426
| +2,392% | +$192K | ﹤0.01% | 5742 |
|
|
2021
Q3 | $8K | Sell |
185
-462
| -71% | -$23.3K | ﹤0.01% | 8212 |
|
|
2021
Q2 | $30K | Sell |
647
-3,590
| -85% | -$171K | ﹤0.01% | 6940 |
|
|
2021
Q1 | $198K | Buy |
4,237
+795
| +23% | +$38.6K | ﹤0.01% | 5498 |
|
|
2020
Q4 | $147K | Buy |
3,442
+750
| +28% | +$38.5K | ﹤0.01% | 5442 |
|
|
2020
Q3 | $132K | Sell |
2,692
-4,306
| -62% | -$238K | ﹤0.01% | 5034 |
|
|
2020
Q2 | $407K | Sell |
6,998
-1,585
| -18% | -$83.7K | ﹤0.01% | 4311 |
|
|
2020
Q1 | $390K | Sell |
8,583
-6,454
| -43% | -$388K | ﹤0.01% | 4181 |
|
|
2019
Q4 | $992K | Buy |
15,037
+5,833
| +63% | +$357K | ﹤0.01% | 4222 |
|
|
2019
Q3 | $532K | Buy |
9,204
+6,810
| +284% | +$422K | ﹤0.01% | 4511 |
|
|
2019
Q2 | $138K | Buy |
+2,394
| New | +$111K | ﹤0.01% | 5158 |
|
|
2019
Q1 | – | Sell |
-4,068
| Closed | -$155K | – | 8015 |
|
|
2018
Q4 | $155K | Buy |
4,068
+1,382
| +51% | +$53.1K | ﹤0.01% | 5156 |
|
|
2018
Q3 | $104K | Buy |
2,686
+954
| +55% | +$36.2K | ﹤0.01% | 5572 |
|
|
2018
Q2 | $65K | Buy |
+1,732
| New | +$60.3K | ﹤0.01% | 5790 |
|
|
2018
Q1 | – | Sell |
-459
| Closed | -$17K | – | 8048 |
|
|
2017
Q4 | $17K | Buy |
459
+141
| +44% | +$5.01K | ﹤0.01% | 6681 |
|
|
2017
Q3 | $12K | Buy |
+318
| New | +$9.99K | ﹤0.01% | 6788 |
|
|
2017
Q2 | – | Sell |
-354
| Closed | -$7K | – | 7877 |
|
|
2017
Q1 | $7K | Sell |
354
-1,954
| -85% | -$36.1K | ﹤0.01% | 6823 |
|
|
2016
Q4 | $44K | Buy |
+2,308
| New | +$38.1K | ﹤0.01% | 5923 |
|
|
2016
Q3 | – | Sell |
-839
| Closed | -$11K | – | 7848 |
|
|
2016
Q2 | $11K | Buy |
839
+391
| +87% | +$5.51K | ﹤0.01% | 6726 |
|
|
2016
Q1 | $7K | Sell |
448
-1,181
| -72% | -$17.3K | ﹤0.01% | 6860 |
|
|
2015
Q4 | $26K | Buy |
1,629
+1,088
| +201% | +$16.5K | ﹤0.01% | 6469 |
|
|
2015
Q3 | $6K | Sell |
541
-474
| -47% | -$6.3K | ﹤0.01% | 7604 |
|
|
2015
Q2 | $14K | Buy |
+1,015
| New | +$14.4K | ﹤0.01% | 7193 |
|
|
2015
Q1 | – | Sell |
-1,772
| Closed | -$25K | – | 9164 |
|
|
2014
Q4 | $25K | Buy |
+1,772
| New | +$26K | ﹤0.01% | 7323 |
|
Other funds holding NRC
VCM
QI
UBS Group's NRC Position: Q1 2026 in Review
UBS Group reduced its NRC Health Common Stock (NRC) stake by 17% in Q1 2026, selling an estimated $81.2K and leaving 23,687 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #6235.
UBS Group first reported a position in NRC in Q4 2014 and has held it in 41 quarters since. The position peaked at $992K in Q4 2019. 121 funds tracked by Wall St. Rank hold NRC as of Q1 2026.
- UBS Group held 23,687 shares of NRC Health Common Stock worth $402K as of Q1 2026.
- UBS Group sold 4,777 NRC Health Common Stock shares in Q1 2026, an estimated $81.2K.
- NRC Health Common Stock made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6235 holding.
- UBS Group first reported a position in NRC Health Common Stock in Q4 2014 and has held it in 41 quarters since.
- UBS Group's NRC Health Common Stock position peaked at $992K in Q4 2019.
- 121 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.